Science

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

Asaf Maoz/LinkedIn

May 9, 2025, 16:45

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Have you seen non-response to immunotherapy in locally advanced dMMR/MSI-H rectal cancer?

We describe such a case with underlying MMR heterogeneity as a potential mechanism of resistance to dostarlimab.”

Title: Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal Adenocarcinoma

Authors: Asaf Maoz, Ronald Bleday, Jeffrey Goldsmith, Shanna A. Matalon, Mark S. Redston, Molly Nestor, NP, Jonathan A. Nowak, Matthew B. Yurgelun

You can read the Full Article on JCO Precision Oncology.

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

More posts featuring Dostarlimab.

Asaf Maoz cancer Dostarlimab Jeffrey Goldsmith Jonathan A Nowak Mark S. Redston Matthew B. Yurgelun Molly Nestor OncoDaily Oncology rectal adenocarcinoma rectal cancer Ronald Bleday Shanna A. Matalon

Hung Trinh: Generation of CAR T Cells Using Lentiviral Vector

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

Ravi B. Parikh: Is Accelerated FDA Approval 23 Times Stronger than the Traditional?

Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One